<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353000</url>
  </required_header>
  <id_info>
    <org_study_id>01-2015</org_study_id>
    <nct_id>NCT02353000</nct_id>
  </id_info>
  <brief_title>Whole Brain Radiotherapy (WBRT) Versus Stereotactic Radiosurgery (SRS) for 4 Upto 10 Brain Metastases</brief_title>
  <acronym>WBRTvsSRS</acronym>
  <official_title>Whole Brain Radiotherapy vs. Stereotactic Radiosurgery for 4 - 10 Brain Metastases:a Phase III Randomized Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently stereotactic radiosurgery (SRS) in 5 up to 10 brain metastases showed to have equal
      survival as in 2 up to 4 brain metastases. Whole brain radiotherapy (WBRT) is currently the
      gold standard for patients with more than 3 brain metastases, but has significant side
      effects. In this prospective randomized phase III trial WBRT is compared to SRS for patients
      with 4 up to 10 BM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dutch guideline advices stereotactic radiosurgery (SRS) for patients with 1 up to 3 brain
      metastases (BM) and whole brain radiotherapy (WBRT) for patients with 4 or more BM. The
      interim analysis from the QUARTZ study showed that WBRT did not provide benefit in quality of
      life nor survival over best supportive care. WBRT has significant side effects, such as hair
      loss, fatigue, and cognitive dysfunction which may impair quality of life. A recently
      published study showed that SRS in patients with 5 up to 10 BM had a comparable survival to
      patients treated with 2 up to 4 BM. Many systemic therapies do not have a satisfactory
      intracranial response, because of the blood-brain barrier. The potential advantages of SRS
      i.e, limiting radiation doses to the uninvolved brain and a high rate of local tumour control
      by just a single treatment. Next logic step would be to compare WBRT with SRS alone in
      patients with 4-10 BM and evaluate whether SRS is superior to WBRT with regard to QOL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life in patients with 4 - 10 brain metastases comparing WBRT and SRS</measure>
    <time_frame>Change in quality of life measured from baseline to 3 months after radiotherapy</time_frame>
    <description>Quality of life is measured by the EQ-5D-5L, a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival steroid use (mg), toxicity including hair loss and fatigue.</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time that patient is functioning independently (Karnofsky ≥ 70)</measure>
    <time_frame>Change in Karnofsky index from baseline to 3 months after radiotherapy</time_frame>
    <description>Time that patient is functioning independently (Karnofsky ≥ 70)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid use</measure>
    <time_frame>Change in steroid use from baseline to 3 months after radiotherapy</time_frame>
    <description>Steroid use in mg over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity measured by hair loss and fatigue</measure>
    <time_frame>Change in toxicity from baseline to 3 months after radiotherapy</time_frame>
    <description>Toxicity measured by hair loss and fatigue using CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of independence</measure>
    <time_frame>Change in independence from baseline to 3 months after radiotherapy</time_frame>
    <description>Degree of independence of patients using the Barthel index</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Brain salvage during follow-up</measure>
    <time_frame>1 year</time_frame>
    <description>Brain salvage during follow-up, type of salvage, and time to salvage after randomisation</description>
  </other_outcome>
  <other_outcome>
    <measure>Verbal learning</measure>
    <time_frame>Change in verbal recall and verbal recognition from baseline to 3 months after radiotherapy</time_frame>
    <description>Verbal recall and verbal regognition is measured using the Hopkins Verbal Learning Test - Revised</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life of cancer patients</measure>
    <time_frame>Change in Quality of life from baseline to 3 months after radiotherapy</time_frame>
    <description>QoL will be measured using the EORTC QLQ-C30</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life of cancer patients with brain neoplasms</measure>
    <time_frame>Change in Quality of life from baseline to 3 months after radiotherapy</time_frame>
    <description>QoL will be measured using the EORTC QLQ-BN20</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life of cancer patients measuring cancer-related fatigue</measure>
    <time_frame>Change in Quality of life from baseline to 3 months after radiotherapy</time_frame>
    <description>QoL will be measured using the EORTC QLQ-FA13</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Stereotactic Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whole Brain Radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases:</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases</description>
    <arm_group_label>Stereotactic Radiosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole Brain Radiotherapy</intervention_name>
    <description>Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases</description>
    <arm_group_label>Whole Brain Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimal 4 up to a maximum of 10 BM on diagnostic MRI scan

          -  Max diameter of single GTV 2.5cm

          -  Max cumulative GTV of 30cm3

          -  Karnofsky performance status ≥ 70

          -  Any solid primary tumour. Small cell lung carcinoma, germinoma, and lymphoma are
             excluded

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Contra-indication for MRI

          -  Prior treatment for BM (i.e. surgery, SRS or WBRT)

          -  Concurrent use of systemic therapy

          -  Maximum cumulative GTV of more than 30cm3 on planning-MRI

          -  More than 10 BM on planning-MRI

          -  A brainstem metastasis with a PTV of more than 20 cm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Lambin, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaap Zindler, MD</last_name>
    <phone>088-4455666</phone>
    <email>Jaap.zindler@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Lambin, Prof. Dr.</last_name>
    <phone>088-4455666</phone>
    <email>phillipe.lambin@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VUmc</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Bruynzeel, MD, Phd</last_name>
      <phone>+31204440436</phone>
      <email>ame.bruynzeel@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edith Dieleman, MD</last_name>
      <phone>+31 20 566 34 33</phone>
      <email>e.m.dieleman@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden MC</name>
      <address>
        <city>Den Haag</city>
        <zip>2262BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruud Wiggenraad, MD, Phd</last_name>
      <phone>+31 70 330 2071</phone>
      <email>r.wiggenraad@haaglandenmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ursula Fisscher</last_name>
      <phone>+31 70 330 2071</phone>
      <email>u.fisscher@haaglandenmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology (MAASTRO clinic)</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaap Zindler, MD</last_name>
      <phone>088 44 55 591</phone>
      <email>jaap.zindler@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Rody Zuidema</last_name>
      <phone>088 44 55 610</phone>
      <email>rody.zuidema@maastro.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemarie Swaak, MD</last_name>
      <phone>+31 10 70 41 347</phone>
      <email>a.swaak@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituut Verbeeten</name>
      <address>
        <city>Tilburg</city>
        <zip>5042BS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bing Oei, MD</last_name>
      <phone>+31 13 594 77 69</phone>
      <email>oei@bvi.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZRTI</name>
      <address>
        <city>Vlissingen</city>
        <zip>4382EK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lieneke van Veelen, MD, Phd</last_name>
      <phone>+31 88 42 70 000</phone>
      <email>l.vanveelen@zrti.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Gijtenbeek JM, Ho VK, Heesters MA, Lagerwaard FJ, de Graeff A, Boogerd W. [Practice guideline 'Brain metastases' (revision)]. Ned Tijdschr Geneeskd. 2011;155(52):A4141. Review. Dutch.</citation>
    <PMID>22217243</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S, Nagano O, Kenai H, Moriki A, Suzuki S, Kida Y, Iwai Y, Hayashi M, Onishi H, Gondo M, Sato M, Akimitsu T, Kubo K, Kikuchi Y, Shibasaki T, Goto T, Takanashi M, Mori Y, Takakura K, Saeki N, Kunieda E, Aoyama H, Momoshima S, Tsuchiya K. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014 Apr;15(4):387-95. doi: 10.1016/S1470-2045(14)70061-0. Epub 2014 Mar 10.</citation>
    <PMID>24621620</PMID>
  </results_reference>
  <results_reference>
    <citation>Zindler JD, Rodrigues G, Haasbeek CJ, De Haan PF, Meijer OW, Slotman BJ, Lagerwaard FJ. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol. 2013 Mar;106(3):370-4. doi: 10.1016/j.radonc.2013.01.015. Epub 2013 Mar 20.</citation>
    <PMID>23522151</PMID>
  </results_reference>
  <results_reference>
    <citation>Langley RE, Stephens RJ, Nankivell M, Pugh C, Moore B, Navani N, Wilson P, Faivre-Finn C, Barton R, Parmar MK, Mulvenna PM; QUARTZ Investigators. Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? Clin Oncol (R Coll Radiol). 2013 Mar;25(3):e23-30. doi: 10.1016/j.clon.2012.11.002. Epub 2012 Dec 2.</citation>
    <PMID>23211715</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

